fda semaglutide obesity has approved a new, higher-dose 7.2 mg weekly injection of #Wegovy (# semaglutide) for long-term weight management in adults with or overweight. 🔹Indication: It is intended as a “step-up” therapy for The FDA approved a pill
Description
Learn more to boost your goals!
Most patients experience noticeable effects within 1-2 weeks, with peak suppression at 16-20 weeks

Robin Piper.
At low doses, GLP-1 agonists have been observed to reduce alcohol cravings, lower the frequency and volume of drinking and in some individuals produce a natural disinterest in alcohol altogether

A TODAY investigation found that medical scams using AI deepfake videos to sell ineffective products are on the rise
_1622902793131_1622902800131.jpg)